Reply: Comment on ‘Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer'

Benzer Materyaller

• Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
  Yazar:: Rowland, A, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers
  Yazar:: Hopkins, Ashley M, ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab
  Yazar:: Hopkins, Ashley M, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab
  Yazar:: Andrew Rowland, ve diğerleri
  Baskı/Yayın Bilgisi: (2020-05-01)
• Nuances to precision dosing strategies of targeted cancer medicines
  Yazar:: Hopkins, Ashley M., ve diğerleri
  Baskı/Yayın Bilgisi: (2020)